This meta-analysis demonstrated that subcutaneous semaglutide significantly reduced body weight by up to 14.9%, improved glycemic control with an average HbA1c reduction of 1.7%, and had a manageable safety profile dominated by gastrointestinal side effects. It involved over 1,961 participants, predominantly adults with obesity, and highlighted semaglutide’s potential to enhance
